Kuros Biosciences’ released its MagnetOS minimally invasive spine delivery system in a full commercial launch.
MagnetOS is a bone graft delivery system and is sterile, prefilled, free of human tissue and has a mechanism of action backed by Level I clinical evidence.
“The launch of MagnetOs MIS is more than a product milestone – it reflects our vision to redefine what’s possible in spine surgery,” Chris Fair, CEO of Kuros, said in a Sept. 30 news release. “By combining efficiency, precision, and the strength of Level I clinical evidence, we’re setting a new standard for minimally invasive care. At Kuros, our mission is to empower surgeons with innovations that don’t just keep pace with the future of surgery but help shape it.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
